Chiome Bioscience Selects ProBioGen for Antibody Manufacturing Program

ProBioGen AG, a service and technology provider for complex therapeutic glycoproteins and Chiome Bioscience Inc, a Japanese antibody discovery and development company, have jointly announced signing a service and license agreement. Under the agreement ProBioGen will apply its enhanced cancer cell-killing technology GlymaxX® to LIV-1205, a clinical candidate in an antibody manufacturing program for Chiome.

Specifically, ProBioGen will develop a stable GlymaxX® cell line, followed by process development and GMP manufacturing of the ADCC-enhanced cancer stem cell antibody, which will be optimised for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) cancer cell-killing activity.

Dr Koji Nakamura, Head of Drug Discovery Laboratories and former CEO of LivTech explained: “We have tested ProBioGen’s GlymaxX® technology for our antibody before and saw in-vivo in animal models an obviously potentiated cancer cell-killing efficacy of its afucosylated version. This, together with our long-standing relationship with the ProBioGen team, the company’s demonstrated track record in developing stable cell lines up to reliable GMP manufacturing for small and big biotechs, and the favourable, royalty-free commercial GlymaxX® Terms, made our selection quite simple.”

ProBioGen’s CEO Wieland Wolf, commented: “We look much forward to a productive partnership which combines Chiome’s outstanding antibody drug candidate, LIV-1205, with our own antibody development expertise and our GlymaxX ADCC enhancement technology to make together with Chiome a marked contribution to combat various cancers.”